Current Developments in Urogenital Infections

A special issue of Microorganisms (ISSN 2076-2607). This special issue belongs to the section "Medical Microbiology".

Deadline for manuscript submissions: 30 April 2025 | Viewed by 1525

Special Issue Editors


E-Mail Website
Guest Editor
Department of Medicine, University of Patras, Metropolitan General Athens, Rio, Greece
Interests: sepsis; COVID-19; immunology of infection
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Urogenital infections represent a significant burden on global public health, affecting millions of individuals worldwide. From urinary tract infections (UTIs) to sexually transmitted infections (STIs) and genital tract infections (GTIs), these conditions pose challenges in diagnosis, treatment, and prevention. As our understanding of the complex interactions between pathogens and the urogenital system deepens, new avenues for research and innovation emerge. We are please to invite you to contribute to this Special Issue of Microorganisms entitled “Current Developments in Urogenital Infections”. This Special Issue aims to provide a comprehensive overview of recent developments in the field of urogenital infections, encompassing a wide range of topics from basic science to clinical applications.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

  • Pathogenesis and microbiology: Insights into the mechanisms of pathogen colonization and invasion in the urogenital tract. Emerging pathogens and antimicrobial resistance patterns in urogenital infections. Microbiota dynamics and their impact on urogenital health and disease.
  • Diagnostic innovations: Novel approaches for the rapid and accurate diagnosis of urogenital infections. Biomarkers and molecular techniques for detecting specific pathogens and assessing disease severity.
  • Therapeutic strategies: Advancements in antimicrobial agents for the treatment of urogenital infections. Precision medicine approaches tailored to individual patient profiles and microbial susceptibilities. Alternative and adjunctive therapies, including probiotics and phage therapy.
  • Prevention: Strategies for the prevention of urogenital infections, including vaccination and behavior modification. Screening programs and risk assessment tools for identifying high-risk populations.
  • Interdisciplinary perspectives: Integration of genomics, proteomics, and bioinformatics in urogenital infection research. Collaboration between microbiologists, clinicians, epidemiologists, and public health experts to address complex challenges.
  • By synthesizing the latest research findings and fostering interdisciplinary dialogue, this Special Issue aims to advance our understanding of urogenital infections and facilitate the translation of scientific discoveries into clinical practice. We invite researchers, clinicians, and public health professionals to contribute their insights and expertise to this collaborative endeavor. "Current Developments in Urogenital Infections" represents a timely opportunity to showcase groundbreaking research and innovations that are shaping the future of urogenital health. Through a multidisciplinary approach, we aim to address the evolving challenges posed by urogenital infections and ultimately improve patient outcomes and public health interventions. We look forward to a vibrant exchange of ideas and discoveries in this exciting field.

Prof. Dr. Charalambos Gogos
Dr. Karolina Akinosoglou
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • urinary tract infection
  • genital tract infection
  • sexually transmitted disease

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 243 KiB  
Article
Antimicrobial Susceptibility of Escherichia coli Isolates Causing Community-Acquired Urinary Tract Infections: Comparison of Methods
by Alexander Machado Cardoso, Vinicius Ribeiro Flores, Gabriel Gomes do Rosario, Juliana Barbosa Succar, Lidiane Coelho Berbert, Maria Clara de Freitas Oliveira, Anna Luiza Bauer Canellas, Marinella Silva Laport, Cláudia Rezende Vieira Mendonça Souza, Thiago Pavoni Gomes Chagas, Rubens Clayton da Silva Dias, Fabio da Silva de Azevedo Fortes and Flávia Lúcia Piffano Costa Pellegrino
Microorganisms 2025, 13(2), 231; https://doi.org/10.3390/microorganisms13020231 - 22 Jan 2025
Viewed by 619
Abstract
Due to bacterial resistance to antimicrobials, antibiotic therapy for urinary tract infections (UTIs) has become a major challenge for clinicians. The present work aimed to compare the antimicrobial susceptibility profiles of 53 uropathogenic Escherichia coli (UPEC) isolates, assessed using the disk diffusion method [...] Read more.
Due to bacterial resistance to antimicrobials, antibiotic therapy for urinary tract infections (UTIs) has become a major challenge for clinicians. The present work aimed to compare the antimicrobial susceptibility profiles of 53 uropathogenic Escherichia coli (UPEC) isolates, assessed using the disk diffusion method and two automated systems (PHOENIX BD™ and VITEK2), with interpretations based on CLSI and BrCAST guidelines. Twenty-five antibiotics were tested to assess differences in susceptibility profiles. Statistical tools, including Kappa coefficient analysis and chi-square tests, were applied to assess concordance and significance between methods. Among the main discrepancies found, BrCAST has classified a greater number of UPEC isolates as resistant to more than half of the antibiotics tested by the disk diffusion method, when compared to CLSI. Although faster, the PHOENIX BD and VITEK2 automated systems exhibited significant discrepancies, with divergences observed for half of the antimicrobials tested. Both automated methods showed discrepancies compared to the disk diffusion method under CLSI and BrCAST guidelines. PHOENIX BD classified some isolates resistant by DD/CLSI as susceptible, while VITEK2 misclassified 25% to 50% of the antimicrobials tested. Conversely, VITEK2 also classified some isolates susceptible to DD/CLSI as resistant to 25% of the antimicrobials tested. Regarding DD/BrCAST, PHOENIX BD classified resistant isolates as susceptible (to 50% of the antimicrobials tested). In comparison, VITEK2 classified resistant isolates as susceptible and susceptible isolates as resistant (25% of the antimicrobials for both). These findings highlight the need for careful selection of susceptibility testing methods, as variations in interpretive criteria between CLSI and BrCAST could impact clinical decision-making. This study underscores the importance of methodological consistency in accurately informing antibiotic therapy in UTI management, especially in the face of rising resistance. Full article
(This article belongs to the Special Issue Current Developments in Urogenital Infections)
Back to TopTop